DiaMedica Therapeutics Inc. (DMAC)
DMAC trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | DMAC on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2018 |
| SEC CIK | 0001401040 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | Canada |
Financials
No annual revenue filed since the period ending 2018-12-31.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "These factors, among others, raise substantial doubt about our ability to continue operations as a going concern which is not alleviated." | 10-Q 2026-11-12 |
| Cash and burn | $6.8M cash; operating cash flow -$8.4M a quarter. | Report 2026-09-30 |
| Shares outstanding | 53,957,474 (2026-11-09); 52,077,439 a year earlier; 37,953,711 three years earlier. | Cover page 2026-11-09 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Baker Tilly US, LLP, Minneapolis, Minnesota, United States | PCAOB Form AP 2026-04-30 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $7.6M, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | Not filed | -$11.3M | -$8.8M | $6.8M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q2 2026 2026-06-30 | Not filed | -$10.1M | -$8.1M | $5.1M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q1 2026 2026-03-31 | Not filed | -$10.0M | -$9.1M | $4.9M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q4 2025 2025-12-31 | Not filed | -$8.7M | -$7.8M | $15.6M | No debt tags | Needs four quarters | 10-K 2026-03-30 |
| Q3 2025 2025-09-30 | Not filed | -$8.6M | -$6.5M | $3.3M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q2 2025 2025-06-30 | Not filed | -$7.7M | -$7.6M | $4.1M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q1 2025 2025-03-31 | Not filed | -$7.7M | -$7.1M | $2.6M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q4 2024 2024-12-31 | Not filed | -$7.9M | -$6.4M | $3.0M | No debt tags | Needs four quarters | 10-K 2026-03-30 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document FORM 424B2 | 424B2 | 2025-08-22 |
| Latest annual report FORM 10-K | 10-K | 2026-03-30 |
| Latest quarterly / interim FORM 10-Q | 10-Q | 2026-11-12 |
| Latest current report FORM 8-K | 8-K | 2026-11-12 |
| Latest proxy FORM DEFA14A | DEFA14A | 2026-04-01 |
Source: SEC EDGAR submissions feed, 429 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -6.1% |
| 1 month | +12.4% |
| 3 months | +30.2% |
| Year to date | +10.4% |
| 1 year | +62.2% |
| From 52-week high | -18.4% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| MPLT | MapLight Therapeutics Inc. | $6.90 | -4.83% | $446.9M |
| OVID | Ovid Therapeutics Inc. | $2.40 | -5.51% | $453.0M |
| ARVN | Arvinas Inc. | $6.77 | -0.73% | $443.3M |
| EOLS | Evolus Inc. | $6.63 | -4.74% | $438.8M |
| ASMB | Assembly Biosciences Inc. | $21.29 | +0.80% | $436.0M |
| BLSM | BlossomHill Therapeutics Inc. | $13.65 | -2.64% | $433.9M |
| CTMX | CytomX Therapeutics Inc. | $1.99 | -2.70% | $432.7M |
| KMDA | Kamada Ltd. | $8.11 | +0.25% | $468.0M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier